

1 A Cost-effectiveness analysis of Nivolumab plus chemotherapy for the first-line treatment of  
2 locally advanced or metastatic gastric/GEJ/oesophageal adenocarcinoma in the United States of  
3 America

4 Jin Zhou<sup>1¶</sup>, Yukai Tang<sup>1¶</sup>, Geli Li<sup>2\*</sup>

5 <sup>1</sup>Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan,  
6 China

7 <sup>2</sup>Department of Oncology, Affiliated Hospital of Xiangnan University,Chenzhou,Hunan,China

8 <sup>¶</sup>1st set of equal contributors.

9 \*Corresponding author

10 E-mail: 19165664057@163.com

11

12

13

14

15

16

17

18

19

20

21

22

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

23

24 **Abstract:**

25 **Background:** Nivolumab in combination with chemotherapy significantly improves survival in  
26 patients with gastric/gastroesophageal junction (G/GEJ)/esophageal adenocarcinoma. The purpose  
27 of this study was to evaluate the cost-effectiveness of Nivolumab plus chemotherapy for  
28 G/GEJ/esophageal adenocarcinoma.

29 **Methods:** A Markov model was developed on the basis of the US healthcare payers' perspectives.  
30 We estimated the costs and summarised their effectiveness as quality-adjusted life-years  
31 (QALYs). One-way and probabilistic sensitivity analyses were conducted to explore the impact of  
32 uncertainties on the cost-effectiveness's results.

33 **Results:** The incremental cost-effectiveness ratios (ICER) for Nivolumab plus  
34 chemotherapy(\$149636.97,1.24QALYs) versus chemotherapy(\$13941.06,0.75QALYs) is  
35 \$135695.91 and the QALYs is 0.49.

36 **Conclusions:** Evidence suggests that Nivolumab plus chemotherapy a for the first-line treatment  
37 of locally advanced or metastatic gastric/GEJ/oesophageal adenocarcinoma may be not a  
38 cost-effective choice.

39 **Keywords:** Cost-Effectiveness; Nivolumab; metastatic gastric/GEJ/oesophageal adenocarcinoma;  
40 Markov model

41

42

43

44

45

## 46 1. Background

47 Gastric/gastroesophageal junction(G/GEJ)/oesophageal adenocarcinoma can be regarded as a  
48 relatively common cancer worldwide, and its incidence is increasing day by day. Nowadays,  
49 gastric cancer is the fifth most common cancer in the world, and its fatality rate ranks the third  
50 among all cancers. From the perspective of geographical distribution, the incidence has increased  
51 significantly in east Asia in recent years, as has North America (1). At present, surgery is still the  
52 preferred treatment for G/GEJ/oesophageal adenocarcinoma. However, the prognosis is bleak and  
53 the postoperative recurrence rate reaches 50%-70% (2, 3). For those patients with unresectable  
54 advanced stage, other methods can only be sought.

55 In recent years, many studies have focused on improving the prognosis of this group of  
56 patients. At present, fluorouracil, platinum and paclitaxel are the main chemotherapy drugs for  
57 advanced G/GEJ/oesophageal adenocarcinoma with negative HER-2, but their therapeutic effect is  
58 not optimistic, and the survival time of most patients receiving chemotherapy is not more than 1  
59 year (4-6). Besides, after the use of targeted therapy combined with chemotherapy for these  
60 patients, their survival was not significantly improved compared with chemotherapy (7-10).

61 Nivolumab is a PD-1 inhibitor. As PD-L1 is expressed more obviously in tumor cells and  
62 tumor immune cells than in normal cells, PD-1 inhibitor has been gradually promoted to a higher  
63 position in tumor therapy. Nivolumab has shown good efficacy in the treatment of many cancers  
64 such as non-small cell lung cancer and renal cell carcinoma (11, 12). Therefore, the Checkmate  
65 649, a phase 3 trial, has been carried out, in which researchers recruited a group of advanced,  
66 unresectable and HER-2 negative patients and randomly divided them into two groups. In addition

67 to the analysis of all patients, PD-L1 CPS $\geq$ 5 patients were singled out for follow-up  
68 analysis. Then, the prognosis of the two groups of patients was compared between the  
69 combination chemotherapy with Nivolumab and chemotherapy alone. In the Result, For patients  
70 with PD-L1 CPS $\geq$ 5, median OS improvement was 3 months (14.4 months [95% CI 13.1 to  
71 16.2] vs 11.1 month [10.0 to 12.1]); Median PFS was 7.7 months (95% CI 7.0 to 9.2) for  
72 combination chemotherapy with Nivolumab compared with 6.05 months (5.0 to 6.9) for  
73 chemotherapy. For all randomized patients, the median OS was 13.1 months (IQR, 6.7 to 19.1) in  
74 the Nivolumab group and 11.1 months (5.8 to 16.1) in the chemotherapy group. In conclusion,  
75 Compared with chemotherapy alone, Nivolumab combined with chemotherapy significantly  
76 improved patient survival, especially in patients with PD-L1 CPS $\geq$ 5 (13).

77 A cost-benefit analysis is necessary before a new drug becomes an approved method of  
78 treatment for many patients. Hence, in this study, based on the results of the Checkmate649  
79 clinical trial, we established an economic model to evaluate the cost-effectiveness of Nivolumab  
80 in combination with chemotherapy in G/GEJ/oesophageal adenocarcinoma.

81

82

83

84

85

86

87

88

89

## 90 2. Materials and Methods

### 91 2.1 Population


92 CheckMate 649 is a randomized phase 3 trial involving 1581 patients from From March 2017  
93 through April 2019 in all over the world. Median progression-free survival (7·7 months [95% CI  
94 7·0–9·2]) was significantly longer in the nivolumab plus chemotherapy group than in the  
95 chemotherapy group (6.05 months [95% CI 5.6–6.9]) in patients with PD-L1 CPS  $\geq 5$ , as was median  
96 overall survival analysis (14·4 months [95% CI 13·1–16·2] vs 11·1 months [10·0–12·1],  
97 respectively) in patients with PD-L1 CPS  $\geq 5$ ). Our data were based on clinical characteristics of  
98 CheckMate 649 subjects aged 18 years or older with previously untreated, unresectable advanced  
99 or metastatic gastric, GEJ, or oesophageal adenocarcinoma, regardless of PD-L1 expression.

100 We focused on the third phase of the CheckMate 649 study. In the total number of people in  
101 this trial, there are 955 patients with PD-L1 CPS  $\geq 5$ . Among them, 473 participants were in the  
102 experimental group (Nivolumab plus chemotherapy) and 482 in the control  
103 group (chemotherapy). We conducted a cost-effectiveness analysis for the Nivolumab plus  
104 chemotherapy group and chemotherapy group to provide a foundation for their different treatment.  
105 The research methods refer to the consolidated health economic evaluation reporting standards  
106 (CHEERS) (see Supplementary Information S1).

### 107 2.2 The Model's Structure

108 The study used TreeAge Software 2021 (TreeAge Software, Inc, Williamstown,  
109 Massachusetts) to programme a multi-state Markov model. The purpose was to evaluate the  
110 cost-effectiveness of Nivolumab plus chemotherapy and chemotherapy in patients with untreated,

111 unresectable advanced or metastatic gastric, GEJ, or oesophageal adenocarcinoma. This was due to  
112 the Markov model being able to provide more flexible modelling assumptions. (14) The multiple  
113 health states include PFS, progressive disease state (PD) and death. Assuming that patients in a  
114 certain state only make one state transition in a cycle, once the patients are in the PD state, they  
115 cannot return to the PFS state. Similarly, the patients in the dead state cannot transition to other  
116 states. The specific transition relationships are shown in Figure 1. We assumed that all the patients  
117 were in a PFS healthy state at the model's initial stage. The patients were treated with Nivolumab  
118 plus chemotherapy or chemotherapy according to their groupings. When the disease progresses,  
119 the follow-up treatment plan in the CheckMate 649 clinical trial is used for treatment until the  
120 patient's death.



121

122 Figure 1. Markov state transition model.

123 We developed a Markov model to simulate the patient's entire life course and evaluate the  
124 cost and effectiveness of first-line therapy for patients with advanced/metastatic gastric, GEJ, or  
125 oesophageal adenocarcinoma. In the CheckMate 649 clinical trial, the median survival time of the  
126 experimental group was 14.4 months, the control group was 11.1 months, and the overall time of  
127 the study is approximately 2 years. The effect of immunotherapy has a delayed effect and may  
128 continue to work beyond the treatment period. It should be analyzed from long-term data to avoid  
129 inaccuracy and uncertainty of results (15, 16). As the result of that, with reference to the dosing

130 cycle of the CheckMate 649 clinical trial, we set the cycle of the Markov model to three weeks  
131 and the time range was 10 years. Approximately 99% of patients were in the absorption state.(17)  
132 A half-circle correction was conducted to simulate the transfer process more accurately.  
133 Simultaneous simulation analysis of the cost and utility is performed to estimate the cumulative  
134 total cost and health outcomes within the cohort's time frame.(18, 19) The research was based on  
135 the American payers' perspectives, with a 3% discount on costs and utilities.(20) According to the  
136 World Health Organization, ICER is acceptable when it is below three times GDP per capita(21).  
137 This study will use three times of the United States's triple GDP per capita in 2021(\$69219.5) as  
138 the threshold(<https://fred.stlouisfed.org/series/A939RC0Q052SBEA>).The WTP is assumed to be  
139 \$207659. The research indicators include the costs, life-years (LYs), quality-adjusted  
140 life-years(QALYs), and the incremental cost-effectiveness ratios (ICERs).

### 141 2.3 The Model's Survival and Progression Risk Estimates


142 The original data for constructing the model were obtained from the CheckMate 649 clinical  
143 trial. When some data were unavailable, we referred to the related published literature. The  
144 GetData Graph Digitiser (version 2.26; <http://getdata-graph-digitizer.com/download.php>) was  
145 used to extract the Kaplan–Meier curve's data of the PFS and OS in the Nivolumab plus  
146 chemotherapy group and the chemotherapy group. We also referred to the algorithm of Guyot et  
147 al. who refers to the pseudo-individual patient's data reconstructed by R software (version 4.1.0;  
148 <https://www.r-project.org/>).(22) This was combined with the Akaike Information Criterion (AIC)  
149 and the Bayesian Information Criterion(BIC) to select the Log-logistic distribution that fitted the  
150 survival curve for Nivolumab plus chemotherapy and chemotherapy respectively after the  
151 reconstruction(eTable 1).(23) The distribution has a higher flexibility and estimated

152 correlations.(24, 25)

153 Table 1 Base-case Analysis

Parameters	Nivolumab plus	
	chemotherapy	Chemotherapy
QALYs	0.75	0.27
Total cost \$	13941.06	17565.97
ICER \$/QALYb	276799.67	
WTP \$/QALY	190239	

154



155

156 Figure2. Tornado diagram for one-way sensitivity analysis.

157 Abbreviation: SD= Stable disease; PD= Disease progression; ICER= Incremental cost-effectiveness ratio.

158 2.4 The Utility and Cost Estimates



159 During the follow-up, the CheckMate 649 trial used the Gastric Cancer Subscale (GaCS) to  
160 compare quality of life after Nivolumab plus chemotherapy vs chemotherapy as the first-line  
161 treatment for advanced gastric cancer/gastroesophageal junction cancer/oesophageal  
162 adenocarcinoma.the average health utility (0.797 for PFS and 0.577 for PD) of the patients with  
163 gastric cancer/gastroesophageal junction cancer/oesophageal adenocarcinoma in the PFS and PD  
164 was obtained by previously published study(26). The top three incidence adverse events(AEs)  
165 with grade 3 or above were selected in Nivolumab plus chemotherapy (nivolumab [360 mg every  
166 3 weeks or 240 mg every 2 weeks]-pluschemotherapy[XELOX every 3 weeks or FOLFOX every  
167 2 weeks], nivolumab-plus-ipilimumab) and chemotherapy to be considered to evaluate the loss of  
168 the health utility caused by the three to five adverse events(AEs) for simplifying the  
169 calculation.The top three incidence adverse events(AEs) with grade 3 or above in Nivolumab plus  
170 chemotherapy and chemotherapy are Neutropenia(14%),Decreased platelet  
171 count(8%),Proteinuria(5%),Increased blood bilirubin(5%), Increased  $\gamma$ -glutamyltransferase(5%)  
172 and Palmar-plantar erythrodysesthesia syndrome(12%), Hypertension(6%), Increased aspartate  
173 aminotransferase (5%), respectively.

174 The costs are reported in 2021 US dollars (US \$1.0 = CNY ¥6.38).Only the direct costs of  
175 the medical expenses were considered. This included the cost of the drugs, subsequent treatment  
176 costs, management costs, follow-up costs, laboratory examination costs, and the major adverse  
177 reactions with grade 3 or above had the top three incidence rates according to CheckMate 649  
178 trial.

179 The drug prices we selected local hospital prices or the price obtained by consulting with the  
180 drug supplier. The estimated cost of each drug during the set period is listed in Table 2. The

181 probability that different treatment groups intend to receive different follow-up treatment and the  
 182 treatment mode of specific subsequent therapies(systemic therapy other than PD-(L)1 inhibitors,  
 183 local regional therapy, radiation therapy, surgery, PD-(L)1 inhibitors) are derived from  
 184 CheckMate 649 trial.

185 Table 2 Model parameters: baseline values, ranges, and distributions for sensitivity analysis.

186 Main model parameters

187 Table 2 Model parameters: baseline values, ranges, and distributions for sensitivity analysis.

188 Main model parameters

Variable (Group:CPS>5 patients)		Range					References
Parameter	Baseline value	Minimum	Maximum	Distribution	Mean	Standard deviation	
<b>survival distribution</b>							
log-logistic of N+ C	PFS Shape=1.648147 Scale=8.546154	-	-	-	-	-	Model fitting
log-logistic of N+ C	OS Shape=1.6508 Scale=14.4888	-	-	-	-	-	Model fitting
log-logistic of C	PFS Shape=1.6508 Scale=14.4888	-	-	-	-	-	Model fitting
log-logistic of C	OS Shape=1.7398 Scale=10.546	-	-	-	-	-	Model fitting
<b>Risk for main adverse events</b>							
<b>Nivolumab plus chemotherapy group</b>							
Neutropenia	0.15	0.12	0.18	Beta	0.15	0.03	Checkmate-649
Neutrophil count decreased	0.11	0.088	0.132	Beta	0.11	0.022	Checkmate-649
Anaemia	0.07	0.056	0.084	Beta	0.07	0.014	Checkmate-649
Diarrhoea	0.05	0.04	0.06	Beta	0.05	0.01	Checkmate-649
<b>Chemotherapy group</b>							
Neutropenia	0.06	0.048	0.072	Beta	0.06	0.012	Checkmate-649
Neutrophil count decreased	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649
Anaemia	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649
Diarrhoea	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649
<b>Health utility scores</b>							
Utility of PFS	0.797	0.6376	0.9564	Beta	0.797	0.1594	[2]
Utility of PD	0.577	0.4616	0.6924	Beta	0.577	0.1154	[2]

<b>Drug cost, \$/per cycle</b>							
Nivolumab-3w	9957.15	7965.72	11948.58	Gamma	9957.15	1991.43	Drugs
Oxaliplatin-3w	521.82	417.456	626.184	Gamma	521.82	104.364	Drugs
Capecitabine-3w	183.3	146.64	219.96	Gamma	183.3	36.66	Drugs
Nivolumab-2w	6638.1	5310.48	7965.72	Gamma	6638.1	1327.62	Drugs
Oxaliplatin-2w	341.19	272.952	409.428	Gamma	341.19	68.238	Drugs
Leucovorin-2w	185.184	148.1472	222.2208	Gamma	185.184	37.0368	Drugs
Fluorouracil-2w	43.62624	34.90099	52.35149	Gamma	332.148	66.42962	Drugs
Radiotherapy	8998.72	6,636.09	13,160.22	Gamma	8998.72	1799.744	[4]
Surgery	20982	10490	41960	Gamma	20982	4196.4	[7]
Paclitaxel	726.57	581.256	871.884	Gamma	726.57	145.314	Drugs
Docetaxel	215.595	172.476	258.714	Gamma	215.595	43.119	Drugs
Carboplatin	165.51	132.408	198.612	Gamma	165.51	33.102	Drugs
Cisplatin	17.064	13.6512	20.4768	Gamma	17.064	3.4128	Drugs
Ramucirumab	143731	114984.8	172477.2	Gamma	143731	28746.2	Drugs
Pembrolizumab	10739.54	8591.632	12887.45	Gamma	10739.5	2147.908	Drugs
<b>Expenditures on main AEs, \$</b>							
Neutropenia	1043	834.4	1251.6	Gamma	1043	208.6	keynote590 D Reaction Tabl
Neutrophil count decreased	466	372.8	559.2	Gamma	466	93.2	keynote590 D Reaction Tabl
Anaemia	1654	1323.2	1984.8	Gamma	1654	330.8	keynote590 D Reaction Tabl
Diarrhoea	3339.64	2671.712	4007.568	Gamma	3339.64	667.928	keynote590 D Reaction Tabl
Follow-up per cycle	59.2	47.36	71.04	Gamma	59.2	11.84	[8]
Laboratory per cycle	157.5	126	189	Gamma	157.5	31.5	[9]
Administration per cycle	69.81	55.848	83.772	Gamma	69.81	13.962	[8]
<b>Disutility due to AEs</b>							
Neutropenia	-0.09	-0.072	-0.108	Beta	-0.09	-0.018	[10]
Neutrophil count decreased	-0.26	-0.208	-0.312	Beta	-0.26	-0.052	
Anaemia	-0.073	-0.0584	-0.0876	Beta	-0.073	-0.0146	[10]

Diarrhoea	-0.05	-0.04	-0.06	Beta	-0.05	-0.01	[10]
<b>Risk for Subsequent therapy</b>							
<b>Nivolumab plus chemotherapy group</b>							
Radiotherapy	0.05	0.04	0.06	Beta	0.05	0.01	Checkmate-649
Surgery	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649
Paclitaxel	0.18	0.144	0.216	Beta	0.18	0.036	Checkmate-649
Docetaxel	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649
Fluorouracil	0.09	0.072	0.108	Beta	0.09	0.018	Checkmate-649
Capecitabine	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649
Oxaliplatin	0.04	0.032	0.048	Beta	0.04	0.008	Checkmate-649
Carboplatin	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649
Cisplatin	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649
Ramucirumab	0.1	0.08	0.12	Beta	0.1	0.02	Checkmate-649
Nivolumab	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649
Pembrolizumab	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649
<b>Chemotherapy group</b>							
Radiotherapy	0.05	0.04	0.06	Beta	0.05	0.01	Checkmate-649
Surgery	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649
Paclitaxel	0.21	0.168	0.252	Beta	0.21	0.042	Checkmate-649
Docetaxel	0.04	0.032	0.048	Beta	0.04	0.008	Checkmate-649
Fluorouracil	0.14	0.112	0.168	Beta	0.14	0.028	Checkmate-649
Capecitabine	0.02	0.016	0.024	Beta	0.02	0.004	Checkmate-649
Oxaliplatin	0.06	0.048	0.072	Beta	0.06	0.012	Checkmate-649
Carboplatin	0.01	0.008	0.012	Beta	0.01	0.002	Checkmate-649
Cisplatin	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649
Ramucirumab	0.1	0.08	0.12	Beta	0.1	0.02	Checkmate-649
Nivolumab	0.03	0.024	0.036	Beta	0.03	0.006	Checkmate-649
Pembrolizumab	0.04	0.032	0.048	Beta	0.04	0.008	Checkmate-649

189

190 The calculated drug dose are based on the actual clinical trials. In the Nivolumab plus  
 191 chemotherapy group, the patients received 360 mg of Nivolumab every 3 weeks or 240 mg every  
 192 2 weeks and chemotherapy (XELOX [capecitabine 1000 mg/m<sup>2</sup> twice daily, days 1–14 and  
 193 oxaliplatin 130 mg/m<sup>2</sup> , day 1, every 3 weeks] or FOLFOX [leucovorin 400 mg/m<sup>2</sup> , day 1,  
 194 fluorouracil 400 mg/m<sup>2</sup> , day 1 and 1200 mg/m<sup>2</sup> , days 1–2, and oxaliplatin 85 mg/m<sup>2</sup> , day 1,  
 195 every 2 weeks]). In the chemotherapy group, the patients received chemotherapy alone. We  
 196 assumed that the average body surface area was 1.68 m<sup>2</sup>.(27)When patients disease progressed, we

197 assumed that all patients whose disease progressed had follow-up treatment. It is important to note  
198 that the systemic therapy other than PD-(L)1 inhibitors in the subsequent therapies for advanced  
199 Gastric cancer, which we chose based on the NCCN 2022.1 guideline, is oxaliplatin, leucovorin  
200 plus fluorouracil therapy (oxaliplatin 85 mg/m<sup>2</sup> IV on day 1, Leucovorin 200 mg/m<sup>2</sup> IV on day  
201 1, 2, fluorouracil 2600 mg/m<sup>2</sup> IV continuous infusion over 24 hours on day 1).

## 202 2.5 Sensitivity Analyses

203 A one-way sensitivity analysis was performed to explore the influence of uncertain parameters on  
204 the ICER.

205 Each parameter was independently changed by assuming  $\pm 20\%$  of the expected value to determine  
206 the obvious influence on decision-making.

207 Probabilistic analysis (PSA) was used to randomly sample all the parameters from a specified  
208 distribution to further explore the uncertainty and relevance of the model's parameters. According  
209 to the parameter type, we selected the appropriate distribution for each uncertain parameter: the  
210 cost of the adverse reactions to drugs and treatment is the gamma distribution. The risk of adverse  
211 reactions, and the health utility scores including PFS, OS, and AE are the beta distribution. We  
212 performed a second-order Monte Carlo simulation of 10,000 iterations and generated a  
213 cost-benefit acceptability curve (CEAC) to show that Nivolumab plus chemotherapy is  
214 cost-effective with different WTP thresholds.

215

216

217

218

219

220

221

222

223 3. Results

224 3.1 Base-case Analysis

225 The result of base-case analysis about the cost and effectiveness of Nivolumab plus  
226 chemotherapy group and chemotherapy group in patients with untreated, unresectable advanced or  
227 metastatic gastric, GEJ, or oesophageal adenocarcinoma was shown in Table 1. According to our  
228 analysis, the incremental cost of Nivolumab plus chemotherapy (\$149636.97, 1.24 QALYs) versus  
229 chemotherapy (\$13941.06, 0.75 QALYs) is \$135695.91 and the QALYs is 0.49. The ICER  
230 values (\$276799.67) are higher than the United States's triple GDP per capita threshold in 2021  
231 (\$207659).


232 3.2 Sensitivity Analyses

233 A one-way sensitivity analysis was used to test the robustness of the two population model  
234 outputs. Under the condition that the input model parameters change by  $\pm 20\%$ , the influence of  
235 each parameter on the analysis results is explored. The results are presented in the tornado diagram  
236 (Figure 2). The sensitivity analysis results demonstrated that the cost of Nivolumab has the most  
237 contributed to it.

238 3.3 Probability sensitivity analysis

239 Probability sensitivity analysis (PSA) is applied to test the bias of the multiple model  
240 parameters on the analysis results when the multiple model parameters change simultaneously.


241 The results are presented through cost-effectiveness acceptability curves (Figure 3) and  
242 incremental cost-effectiveness scatterplots (Figure 4). According to the results, we found that the  
243 higher the average social willingness to pay, the higher the probability of Nivolumab plus  
244 chemotherapy producing the cost effect. Under the condition of a payment threshold of \$207659  
245 per QALY, Probabilistic sensitivity analysis showed that there was 1.49% probability that  
246 Nivolumab plus chemotherapy was cost-effective within the fluctuation range of other model  
247 parameters in first-line in advanced gastric, GEJ, or oesophageal adenocarcinoma.



248  
249 Figure3. Acceptability Curves for the choice of sintilimab plus IBI305 versus sorafenib at  
250 different WTP thresholds in patients in the treatment of hepatocellular carcinoma.

251 Abbreviation: WTP= Willingness to pay.

252



253

254

Figure4. Incremental cost-effectiveness scatterplots

255

We also conducted subgroup analysis of the patients with PD-L1 CPS $\geq$ 5 according to

256

Median age (IQR),Race(Asian or Non-Asian),Region (Asia or United States and Canada or Rest

257

of world),Primary tumour location at initial diagnosis (GC or GEJC or EAC), the value of Tumour

258

cell PD-L1 expression , Eastern Cooperative Oncology Group performance status(0 or 1),Prior

259

surgery(yes or no), the number of Organs with metastases, Signet ring cell carcinoma(yes or no),

260

Lauren classification (Intestinal type or Diffuse type or Mixed or Unknown), MSI status (MSS or

261

MSI-H or Not reported or invalid),Chemotherapy regimen(FOLFOX or XELOX ),Disease stage

262

(Metastatic or Locally advanced or Locally recurrent ), Site of metastases (Liver

263

Or Peritoneum or CNS) according to the survival of subgroups of patients in CheckMate 649.

264

Unfortunately,all subgroup analysis factors are all not likely to be cost effective when the payment

265

threshold Less than or equal to \$207659 per QALY.

266



267 4. Discussion

268 Fluoropyrimidine plus platinum-based chemotherapy is a first-line treatment for unresectable  
269 advanced or metastatic human epidermal growth factor receptor 2 (HER2) negative gastric and  
270 GEJ adenocarcinoma, but its efficacy is poor. The study subjects included in CheckMate 649 are  
271 patients with advanced/metastatic gastric cancer/gastroesophageal junction cancer/oesophageal  
272 adenocarcinoma with negative HER2. Nivolumab plus chemotherapy was compared with  
273 chemotherapy to evaluate whether Nivolumab plus chemotherapy could be used as first-line  
274 therapy for gastric/GEJ/oesophageal adenocarcinoma patients with negative HER2 .The result of  
275 CheckMate 649 showed that Nivolumab plus chemotherapy had significantly improved median  
276 survival time and median progression-free survival time compared to chemotherapy.Although  
277 Nivolumab plus chemotherapy has considerable efficacy in patients with gastric/GEJ/oesophageal  
278 adenocarcinoma, economic factors cannot be ignored. Many cancer patients are often forced to  
279 ignore the most effective drugs for their treatment because of high drug prices and treatment costs.  
280 Therefore, in order to avoid wasting medical resources, it is necessary to conduct a cost-benefit  
281 analysis.

282 Based on CheckMate 649 clinical trials and the latest population data and drug prices in  
283 USA, Our study is the first to evaluate whether Nivolumab plus chemotherapy is more  
284 cost-effective than chemotherapy as first-line treatment for patients with gastric/GEJ/oesophageal  
285 adenocarcinoma from the American payers' perspectives.We obtained the data of Nivolumab  
286 plus chemotherapy group and chemotherapy group through the clinical trial CheckMate 649, so  
287 we could only conduct cost-effectiveness analysis on these two groups.Our analysis shows that  
288 with a WTP threshold of \$207659/QALY for the two groups ,the Nivolumab plus chemotherapy

289 group may not be cost-effective to be the first-line for gastric/GEJ/oesophageal adenocarcinoma.

290 We also performed subgroup analyses for all the subgroups mentioned in the clinical trials,

291 unfortunately, the subgroup analysis implied that Nivolumab plus chemotherapy was not a

292 cost-effective strategy across all the patient subgroups.

293 One-way sensitivity analysis demonstrated that reducing the cost of drugs was the most

294 influential factor to the result of cost-effectiveness. Since the therapeutic effect of the

295 experimental group was better than that of the control group, and chemotherapy was in the control

296 group, the price largely determines the cost-effectiveness. The lower the price of capecitabine ,

297 oxaliplatin , leucovorin and fluorouracil, the lower the cost-effectiveness of the experimental

298 group. There also have been some economic studies on chemotherapy for gastric/GEJ/oesophageal

299 adenocarcinoma, but mainly compared with chemotherapy regimens such as FOLFOX and

300 XELOX. Chemotherapy is much less expensive than immunotherapy in most cases, so it is easier

301 to show cost-effectiveness. Another cost-benefit analysis of Atezolizumab and bevacizumab

302 combination compared with sorafenib in unresectable hepatocellular carcinoma also showed that

303 the immunotherapy group was not cost-effective compared to sorafenib alone(28). Therefore, We

304 conclude that PD-1 inhibitors may be difficult to recommend as cost-effectiveness options for

305 first-line recommendations in advanced gastric/GEJ/oesophageal adenocarcinoma.

306 We found that when the cost of Nivolumab plus chemotherapy was reduced by

307 23%,respectively, the ICER was \$207659 /QALY which was cost-effective. Therefore, changing

308 the price of Nivolumab plus chemotherapy is an effective feasible strategy to achieve efficient use

309 of them. medical insurance authority could negotiate with pharmaceutical companies to ensure

310 reasonable drug prices and adjust the medical insurance list to reduce the medical burden on

311 patients.

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

## 332 5.Limitations

333 Our study has some limitations. First, CheckMate 649 is a phase three randomised controlled  
334 trial, and we used this model to simplify the study. For instance, regarding the adverse reactions,  
335 we selected the three to four main AEs that would lead to errors. Second, the study's data  
336 originated from the CheckMate 649 trial. Due to the limitation of the number of patients included  
337 in the trial, we could not perform a larger-scale analysis, and the trial did not provide the  
338 follow-up survival data for patients. We relied on the survival data based on the trial and  
339 performed a reasonable extrapolation to predict the long-term survival of patients. This will  
340 inevitably be different from the data of real-world patients obtained through regular follow-ups.  
341 Third, since CheckMate 649 does not disclose the specific health data of patients, our PFS and PD  
342 effectiveness were derived from previously published related studies. This may be different from  
343 the actual situation of the study. Fourth, we only considered the cost impact and utility reduction  
344 caused by the three to four main AEs. The utility reduction caused by specific adverse reactions  
345 comes from other published literature, which is in line with the real situation. Fifth , the clinical  
346 trial is a multicentred and comprehensive study between different countries and races. The  
347 treatment plan of the trial, and especially the follow-up treatment of patients, will be adjusted  
348 appropriately according to the specific situation. Therefore, more clinical trials are still required to  
349 reduce the study population, follow-up treatment, and other factors that impact the results.

350

351

352

353

354 6. Conclusion

355 Overall, from the Americans payers' perspectives, compared with chemotherapy, Nivolumab  
356 plus chemotherapy a for the first-line treatment of patients aged 18 years or older who were  
357 clinically or pathologically diagnosed with locally advanced or metastatic  
358 gastric/GEJ/oesophageal adenocarcinoma may be not a cost-effective choice at a WTP threshold  
359 of \$207659 /QALY.

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376 Acknowledgements

377 The authors wish to acknowledge Dr Xiang-ping Li, Professor of Department of Pharmacy,  
378 Xiangya Hospital, Central South University, for his help in interpreting the significance of the  
379 results of the study. And also acknowledge Dr Qin Zhou, Professor of Department of Oncology,  
380 Xiangya Hospital, Central South University, for support funding to this study.

381 Reference:

- 382 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics  
383 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185  
384 countries. *CA Cancer J Clin.* 2018;68(6):394-424.
- 385 2. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, et al. Gastric Cancer,  
386 Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. *Journal of the National*  
387 *Comprehensive Cancer Network : JNCCN.* 2016;14(10):1286-312.
- 388 3. Gunderson LL. Gastric cancer--patterns of relapse after surgical resection. *Semin Radiat*  
389 *Oncol.* 2002;12(2):150-61.
- 390 4. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric  
391 cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of*  
392 *oncology : official journal of the European Society for Medical Oncology.* 2016;27(suppl  
393 5):v38-v49.
- 394 5. Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, et al. The Chinese Society of  
395 Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric  
396 cancer. *Cancer communications (London, England).* 2019;39(1):10.
- 397 6. Japanese Gastric Cancer A. Japanese gastric cancer treatment guidelines 2018 (5th

- 398 edition). *Gastric Cancer*. 2021;24(1):1-21.
- 399 7. Catenacci DVT, Tebbutt NC, Davidenko I, Murad AM, Al-Batran SE, Ilson DH, et al.  
400 Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced  
401 MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised,  
402 double-blind, placebo-controlled, phase 3 trial. *The Lancet Oncology*. 2017;18(11):1467-82.
- 403 8. Fuchs CS, Shitara K, Di Bartolomeo M, Lonardi S, Al-Batran SE, Van Cutsem E, et al.  
404 Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with  
405 metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised,  
406 placebo-controlled, phase 3 trial. *The Lancet Oncology*. 2019;20(3):420-35.
- 407 9. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and  
408 cisplatin with or without cetuximab for patients with previously untreated advanced gastric  
409 cancer (EXPAND): a randomised, open-label phase 3 trial. *The Lancet Oncology*.  
410 2013;14(6):490-9.
- 411 10. Shah MA, Bang YJ, Lordick F, Alsina M, Chen M, Hack SP, et al. Effect of Fluorouracil,  
412 Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive  
413 Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial. *JAMA Oncol*.  
414 2017;3(5):620-7.
- 415 11. Ando K, Kishino Y, Homma T, Kusumoto S, Yamaoka T, Tanaka A, et al. Nivolumab plus  
416 Ipilimumab versus Existing Immunotherapies in Patients with PD-L1-Positive Advanced  
417 Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-Analysis. *Cancers*  
418 (Basel). 2020;12(7).
- 419 12. Edwards SJ, Wakefield V, Cain P, Karner C, Kew K, Bacelar M, et al. Axitinib,

420 cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated  
421 renal cell carcinoma: a systematic review and economic evaluation. Health technology  
422 assessment (Winchester, England). 2018;22(6):1-278.

423 13. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line  
424 nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric,  
425 gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a  
426 randomised, open-label, phase 3 trial. The Lancet. 2021;398(10294):27-40.

427 14. Verma V, Sprave T, Haque W, Simone CB, 2nd, Chang JY, Welsh JW, et al. A  
428 systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.  
429 Journal for immunotherapy of cancer. 2018;6(1):128.

430 15. Othus M, Bansal A, Koepl L, Wagner S, Ramsey S. Accounting for Cured Patients in  
431 Cost-Effectiveness Analysis. Value in health : the journal of the International Society for  
432 Pharmacoeconomics and Outcomes Research. 2017;20(4):705-9.

433 16. Bullement A, Latimer NR, Bell Gorrod H. Survival Extrapolation in Cancer  
434 Immunotherapy: A Validation-Based Case Study. Value in health : the journal of the  
435 International Society for Pharmacoeconomics and Outcomes Research. 2019;22(3):276-83.

436 17. Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. Methods in  
437 molecular biology (Clifton, NJ). 2009;471:469-86.

438 18. Huang M, Lou Y, Pellissier J, Burke T, Liu FX, Xu R, et al. Cost Effectiveness of  
439 Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic  
440 NSCLC that Expresses High Levels of PD-L1 in the United States. Pharmacoeconomics.  
441 2017;35(8):831-44.



- 442 19. Lin S, Luo S, Zhong L, Lai S, Zeng D, Rao X, et al. Cost-effectiveness of atezolizumab  
443 plus chemotherapy for advanced non-small-cell lung cancer. *Int J Clin Pharm.*  
444 2020;42(4):1175-83.
- 445 20. Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al.  
446 Recommendations for Conduct, Methodological Practices, and Reporting of  
447 Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine.  
448 *Jama.* 2016;316(10):1093-103.
- 449 21. Thokala P, Ochalek J, Leech AA, Tong TJP. Cost-effectiveness thresholds: the past, the  
450 present and the future. 2018;36(5):509-22.
- 451 22. Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival  
452 data: reconstructing the data from published Kaplan-Meier survival curves. *BMC Med Res*  
453 *Methodol.* 2012;12:9.
- 454 23. Liu M, Zhang L, Huang Q, Li N, Zheng B, Cai H. Cost-Effectiveness Analysis Of Ceritinib  
455 And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive  
456 Advanced Non-Small Cell Lung Cancer. *Cancer Manag Res.* 2019;11:9195-202.
- 457 24. Zhang L, Zeng X, Cai H, Li N, Liu M, Qiu L, et al. Cost-effectiveness of second-line  
458 nivolumab for platinum-treated advanced non-small-cell lung cancer. *J Comp Eff Res.*  
459 2020;9(18):1301-9.
- 460 25. Wang X, Jin L, Cui J, Ma K, Chen X, Li W. Mouse double minute-2 homolog  
461 (MDM2)-rs2279744 polymorphism associated with lung cancer risk in a Northeastern Chinese  
462 population. *Thoracic cancer.* 2015;6(1):91-6.
- 463 26. Chen HD, Zhou J, Wen F, Zhang PF, Zhou KX, Zheng HR, et al. Cost-effectiveness

464 analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer. J Cancer

465 Res Clin Oncol. 2017;143(2):361-8.

466 27. Ward MC, Shah C, Adelstein DJ, Geiger JL, Miller JA, Koyfman SA, et al.

467 Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer. Oral Oncol.

468 2017;74:49-55.

469 28. Lam SW, Wai M, Lau JE, McNamara M, Earl M, Udeh B. Cost-Effectiveness Analysis of

470 Second-Line Chemotherapy Agents for Advanced Gastric Cancer. Pharmacotherapy.

471 2017;37(1):94-103.

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

487

488

489

490

491 Ethics approval

492 This study was based on a literature review and modelling techniques; this study did not require

493 approval by an institutional research ethics board.

494 Disclaimer

495 The views expressed are those of the authors. The funding agencies played no role in the study

496 design, data collection and analysis, decision to publish, or manuscript preparation.

497 Provenance and peer review

498 Not commissioned; externally peer reviewed.

499 Data sharing statement

500 No additional data are available.

501 Supplemental material

502 Supplemental material for this article is available online.

503 Figures and legends

504 Figure1.Markov state transition model.

505 Figure2. Tornado diagram for one-way sensitivity analysis.

506 Figure3. Acceptability Curves.

507 Figure4.Incremental cost-effectiveness scatterplots.

508 Ethics approval and consent to participate

509 Not applicable

510 Consent for publication

511 Not applicable

512

513 Availability of data and materials

514 Data sharing is not applicable to this article as no datasets were generated or analysed during the

515 current study.

516 Conflict of interest

517 The authors declare that there is no conflict of interest.

518 Funding

519 This study was funded by the Natural Science Foundation of Hunan Province for Young Scholars

520 (No. 2020JJ5957; Project Recipient: QZ).

521 Authors' contributors

522 Mr Zhou and Mr Tang had full access to all of the data in the study and takes responsibility for the

523 integrity of the data and the accuracy of the data analysis.

524 Concept and design: Li.

525 Acquisition, analysis, or interpretation of data: Zhou, Tang.

526 Drafting of the manuscript: Zhou, Tang, Li.

527 Critical revision of the manuscript for important intellectual content: Tang.

528 Statistical analysis: Zhou, Tang.

529 Obtained funding: Zhou.

530 Administrative, technical, or material support: Zhou, Tang.

531 Supervision: Tang.

532